Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy

Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy

Abstract Whether patients with advanced hepatocellular carcinoma (aHCC) benefit from hepatitis C virus (HCV) eradication is uncertain. We aimed to investigate whether a survival benefit was conferred by HCV eradication in aHCC patients. This retrospective cohort study enrolled 168 HCV‐infected aHCC...

Full description

Bibliographic Details
Main Authors:	Ming‐Lun Yeh, Hsing‐Tao Kuo, Ching‐I Huang, Chung‐Feng Huang, Ming‐Yen Hsieh, Po‐Cheng Liang, I‐Hung Lin, Meng‐Hsuan Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang
Format:	Article
Language:	English
Published:	Wiley 2021-02-01
Series:	Kaohsiung Journal of Medical Sciences
Subjects:	direct acting antivirals hepatitis C virus hepatocellular carcinoma Sorafenib survival
Online Access:	https://doi.org/10.1002/kjm2.12303

Similar Items

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment
by: Ming‐Lun Yeh, et al.
Published: (2019-10-01)

Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma
by: Zu‐Yau Lin, et al.
Published: (2021-07-01)

Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression
by: Zu‐Yau Lin, et al.
Published: (2022-02-01)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
by: Po‐Yao Hsu, et al.
Published: (2022-01-01)

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study
by: Ming-Lun Yeh, et al.
Published: (2016-11-01)

Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication
by: Chung‐Feng Huang, et al.
Published: (2020-11-01)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
by: Po-Yao Hsu, et al.
Published: (2021-01-01)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients.
by: Jee-Fu Huang, et al.
Published: (2015-01-01)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients
by: Ching-I Huang, et al.
Published: (2017-08-01)

Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma
by: Ming-Lun Yeh, et al.
Published: (2015-02-01)

Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection
by: Chung-Feng Huang, et al.
Published: (2015-05-01)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma.
by: Ming-Lun Yeh, et al.
Published: (2017-01-01)

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2019-01-01)

Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib
by: Meng-Chuan Lu, et al.
Published: (2023-05-01)

Association of hyperuricemia with disease severity in chronic hepatitis C patients.
by: Tyng-Yuan Jang, et al.
Published: (2018-01-01)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
by: You-Liang Lai, et al.
Published: (2022-01-01)

Association between gallbladder stones and chronic hepatitis C: Ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan
by: Chia-Yen Dai, et al.
Published: (2013-08-01)

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2015-01-01)

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
by: Ming-Lung Yu, et al.
Published: (2018-06-01)

Hepatitis C Virus Infection And Metabolic Syndrome—A Community-Based Study in an Endemic Area of Taiwan
by: Jee-Fu Huang, et al.
Published: (2009-06-01)

Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.
by: Chung-Feng Huang, et al.
Published: (2013-01-01)

Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan
by: Pei‐Chien Tsai, et al.
Published: (2022-07-01)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
by: I-Cheng Lee, et al.
Published: (2022-10-01)

Glucose abnormalities in hepatitis C virus infection
by: Jee-Fu Huang, et al.
Published: (2013-02-01)

Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
by: Tzu‐Sheng Cheng, et al.
Published: (2021-04-01)

Itemization difference of patient-reported outcome in patients with chronic liver disease
by: Ming-Chieh Lin, et al.
Published: (2022-01-01)

Unawareness of hepatitis B infection and lack of surveillance are associated with severity of hepatocellular carcinoma
by: Kuan‐I Lee, et al.
Published: (2023-11-01)

A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma
by: Mai-Huong T. Ngo, et al.
Published: (2021-07-01)

Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients.
by: Jee-Fu Huang, et al.
Published: (2017-01-01)

Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
by: Zu-Yau Lin, et al.
Published: (2023-10-01)

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
by: Yi-Shan Tsai, et al.
Published: (2022-04-01)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
by: Yi-Shan Tsai, et al.
Published: (2020-07-01)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
by: Ying-Chou Huang, et al.
Published: (2021-01-01)

Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules
by: Zu‐Yau Lin, et al.
Published: (2020-06-01)

Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection
by: Ta-Ya Lin, et al.
Published: (2017-06-01)

The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases
by: Yi-Hung Lin, et al.
Published: (2016-07-01)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
by: Song-Fong Huang, et al.
Published: (2022-09-01)

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
by: Tsai Jung-Fa, et al.
Published: (2005-04-01)

Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis
by: Jee-Fu Huang, et al.
Published: (2020-01-01)

Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan
by: Chen-Yuan Lin, et al.
Published: (2021-01-01)